1. Home
  2. FINW vs ELTX Comparison

FINW vs ELTX Comparison

Compare FINW & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FinWise Bancorp

FINW

FinWise Bancorp

HOLD

Current Price

$13.73

Market Cap

194.4M

Sector

Finance

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$3.02

Market Cap

185.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FINW
ELTX
Founded
1999
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
194.4M
185.4M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
FINW
ELTX
Price
$13.73
$3.02
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$18.00
AVG Volume (30 Days)
43.0K
1.1M
Earning Date
04-30-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
21.51
39.29
EPS
0.20
N/A
Revenue
N/A
$2,301,000.00
Revenue This Year
$160.48
N/A
Revenue Next Year
$35.27
N/A
P/E Ratio
$67.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.82
$2.66
52 Week High
$22.49
$16.00

Technical Indicators

Market Signals
Indicator
FINW
ELTX
Relative Strength Index (RSI) 45.44 35.97
Support Level $13.28 $2.72
Resistance Level $14.70 $9.62
Average True Range (ATR) 0.67 0.30
MACD -0.05 0.25
Stochastic Oscillator 48.59 28.33

Price Performance

Historical Comparison
FINW
ELTX

About FINW FinWise Bancorp

FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: